

Registered number: 57125
Charity number: CHY 6100
CRA number: 20010270

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

DIRECTORS' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2020

ASTHMA SOCIETY OF IRELAND

CONTENTS

	Page
Directors and Other Information	1
Directors' Report	2-15
Directors' Responsibilities Statement	16
Independent Auditor's Report	17-19
Statement of Financial Activities	20
Balance Sheet	21
Statement of Cash Flows	22
Notes to the Financial Statements	23-38

ASTHMA SOCIETY OF IRELAND

DIRECTORS AND OTHER INFORMATION

Directors	David Clancy, Chairperson (appointed 29/06/2021) Allan Kearns (resigned 29/06/2021) Ciaran McGloin Lorna Jennings Vincent Butterly Ciara Kelly Sharon Edge Marcus Butler James Dunny Dermot Nolan (resigned 09/03/2021) Liam Osborne Catherine Lonergan (appointed 06/05/2020) Hilary Gormley (appointed 08/02/2021) Henry Minogue (appointed 29/06/2021)
Company Secretary	Ciaran McGloin
Chief Executive Officer	Sarah O'Connor
Interim Chief Executive Officer	Emily Blennerhassett
Director Emeritus	Anne Robinson
Company registered number	57125
Charity registered number	CHY 6100
Charities Regulatory Authority number	20010270
Registered office	3rd Floor 42-43 Amiens Street Dublin 1
Independent auditor	Mazars Chartered Accountants & Statutory Audit Firm Harcourt Centre Block 3 Harcourt Road Dublin 2
Principal Bankers	Bank of Ireland 2 College Green Dublin 2 AIB Bank George's Street Dun Laoghaire Co Dublin
Solicitors	Sherwin O'Riordan 74 Pembroke Road Ballsbridge Dublin 4

ASTHMA SOCIETY OF IRELAND

DIRECTORS' REPORT for the year ended 31 December 2020

The Directors present their annual report and audited financial statements for the year ended 31 December 2020.

DIRECTORS AND COMPANY SECRETARY

The Directors and Secretary who served during the year are set out on page 1.

PRINCIPAL ACTIVITIES AND OBJECTIVES

The Asthma Society of Ireland ("Asthma Society", "the Society" or "ASI") is the voice of asthma in Ireland. We champion change to prevent asthma deaths. We communicate about asthma to ensure it is taken seriously as a health challenge. We support with services for all people with asthma, empowering them to control the condition and providing health promotion programmes. We learn together and collaborate with healthcare, research and education professionals to improve our understanding of how asthma works and how to combat it.

Our vision is that everyone in Ireland with asthma lives a full life, symptom free. Our mission is to eliminate asthma deaths and transform the lives of people with asthma.

BUSINESS REVIEW AND FINANCIAL RESULTS

2020 was a hugely challenging and hugely productive and impactful year for the Asthma Society. As a respiratory charity during a global respiratory pandemic, the Society grew the scale of its services, and saw its engagements with the public and with healthcare professionals rise significantly, particularly for the six months following the pandemic outbreak. By necessity, the aim and objectives of our awareness, advocacy, patient services and research programmes and activity changed from what had been originally envisioned for 2020, but the corresponding scale of the Society's impact was also transformed from its previous footprint in the Irish healthcare sector.

Like many other charities, the Society was forced to pause provision of some funded services and a substantial amount of its fundraising initiatives in line with COVID-19 restrictions.

While the Society returned a deficit for the year, overall, 2020 saw substantial changes in how the funding was generated. The Society and the team worked to be agile about income generation and fundraising, and worked with longstanding existing funding partners to adapt workflows and existing agreements to take into account the changing needs of asthma patients during the pandemic.

The 2020 deficit is €86,347. The Board acknowledges that 2021 has proven to be a more challenging year financially to date but is projecting an improved outlook for 2022. The Board believes the fundraising strategy and resourcing of the team and the potential of the Society's programmes going forward can put the Society on a much improved financial footing.

While the challenge to support patients through the COVID-19 pandemic dominated the work in 2020, the Society is now focussed on the important task of increasing the statutory funding available to support the awareness building work of the organisation, which has increased in importance and impact year-on-year over the last four years. The Society is generating a strategy to consolidate and increase statutory funding in 2021. The funding by the Sláintecare Integration Fund of the Society's new Beating Breathlessness nurse-led WhatsApp service was a major factor in the increased statutory funding position in 2020, alongside the adaptation of utilisation of funding streams to roll out activity across the social inclusion area of the Society's work, which had been accrued over a number of years.

In terms of fundraising, there were substantial changes for the organisation in 2020. The Board of the Society took a decision to end the Superdraw in 2020. Income from Trusts and Foundations was up in 2020, as the Society worked to build important relationships with funders to support its patient services through the pandemic.

Digital fundraising became more important in 2020 and the 10 Million Steps for Asthma virtual fundraiser and COVID-19 Crisis Appeal to members of the Society served to bolster the fundraising income. Community fundraising through mass collections and events were down on 2019, as these were not possible to run with COVID-19 restrictions but individuals continue to support the Society through their efforts on our behalf. One major "in memory" legacy donation served to support the Society in 2020 and allowed it to continue to support many patients through the pandemic.

ASTHMA SOCIETY OF IRELAND

DIRECTORS' REPORT for the year ended 31 December 2020

BUSINESS REVIEW AND FINANCIAL RESULTS (Continued)

Our corporate donor income decreased in 2020 as long-standing partnerships were impacted by the COVID-19 pandemic. This trend is also observable into 2021 but is identified as a major target for fundraising growth in 2022, particularly in respect of unrestricted corporate donations.

Overall, income grew by 14% in 2020, a moderate increase on 2019 largely evident in the first two quarters of the year before COVID-19 began to make a serious financial impact. In Q4, 2020, the Society undertook cost-cutting measures to allow for the change in financial position as originally planned and projected for the year. A number of short-term staff contracts were not renewed and all programmes were scrutinised for possible savings, which were made. These efforts were re-visited in Q2-Q3 2021 to stabilise the Society as the long tail of COVID-19 continued to make it a challenging period for the Society.

Gross income for the year was made up as follows:

	2020	2019
	€	€
HSE and other Statutory Funding	435,564	301,025
Community fundraising, donations, membership and other income	327,418	163,818
Superdraw receipts (paused in Q2 and formally ceased November 2020)	251,501	359,967
Corporate sponsorship and charitable trust income	205,550	244,506
Investment income	46	47
Total	1,220,079	1,069,363

The Society's expenditure in 2020 was €1,306,426 (2019: €1,126,734). Taking into account the cost of fundraising, the Society's net deficit in 2020 was €86,347 (2019: €57,371).

RESERVES POLICY

The Board recognises the need to hold reserves to ensure the financial stability of the Society and to protect the Society from the risk of significant future loss of income. In particular, the Board recognises the need to acquire new funding streams and to pursue further unrestricted revenue streams.

A new Fundraising Strategy is currently being formulated with the aim of diversifying income streams and ensure financial sustainability. The Society has envisioned that this plan would lead to a wider range of income sources, making it significantly less vulnerable to the loss of any one source of income, and further work is being undertaken in order to consolidate this diversification.

The Society is working to build the level of unrestricted funds. Annually, the Board reviews the level of activities of the Society to determine the minimum level of reserves needed to meet its minimum funding policy. The Executive of the Society monitors the reserves on an ongoing basis and the Board formally reviews its reserves policy on an annual basis to ensure it remains appropriate for the financial stability of the Society, or more frequently when required.

It is also the policy of the Society to hold sufficient reserves to fund its activities and maintain the quality of its services for a minimum period of 4 months, plus redundancy costs. For the current year, this equates to approximately €435,475. The Board acknowledges that the current balance of unrestricted funds of €283,001 does not meet this requirement. As noted in the risk section of the Directors' Report, there is an additional focus on this and plans are being implemented to address this issue.

ASTHMA SOCIETY OF IRELAND

DIRECTORS' REPORT (continued) for the year ended 31 December 2020

ACHIEVEMENTS AND PERFORMANCE

The Asthma Society has had one of the busiest, most productive and most impactful years of its existence in 2020.

The Exceptional – Integrated Supports across Advocacy, Awareness and Information Provision, Research and Patient Services to meet the demands of COVID-19

While the pandemic was unforeseen in early 2020, the Asthma Society board and team met the challenges it posed by focussing on meeting immediate and pressing patient needs. We responded quickly and efficiently, pausing programmes that were undeliverable and focussing on projects that could be delivered and scaled remotely, providing supports to patients safe in their homes.

It was a whole-of-organisation approach, where each function worked closely together to improve our learning, our delivery of service to patients and the outcomes we were able to deliver for patients and their carers.

We responded to six major waves of concern/patient support from March to December. Each wave involved drafting relevant patient materials (in conjunction with our Medical Advisory Group and the Clinical Programme for Asthma), creating content, engaging with media, engaging with our patients and tailoring our services to meet the changing needs of patients.

Wave 1 – What is COVID-19

Wave 2 – Asthma Medication supply concerns

Wave 3 – Asthma / Chronic Obstructive Pulmonary Disease (COPD) and COVID-19 FAQ development/updates – dissemination through digital / media

Wave 4 – What do Patients Need? Asthma Awareness Week, patient survey, Beating Breathlessness Launch

Wave 5 – Restrictions changes – Cocooning and Restrictions lifting

Wave 6 – Return to Work / Back2School / Winter Wellness

Further details on this work appear in the most relevant section below.

The Society's key activities that help save and improve the lives of people with asthma are:

1. We Champion Change – Advocacy

Political Lobbying and Advocacy Campaigns – General Election 2020. The General Election presented an important opportunity for the Asthma Society of Ireland to highlight our policy priorities and seek support among potential and established political actors. We sought to secure commitments from future Teachtaí Dála in recognition of the needs and rights of people with asthma and COPD through our #AsthmaMatters manifesto outlining six priorities we wished to see adopted by the 33rd Dáil. Our #AsthmaMatters campaign, including election infographics and a Facebook Live, achieved 176.3k impressions on Twitter and had a reach of 73,000 on Facebook over the campaign.

Political Lobbying and Advocacy Campaigns – Programme for Government. Following General Election 2020, we undertook outreach to all parties involved in government formation talks and, later, programme for government negotiations to seek commitments to our #AsthmaMatters actions and our research on asthma patient COVID-19 concerns. Commitments included in the Programme for Government that aligned with the Asthma Society's priorities included publishing the first ever clean air strategy and the prioritisation of older people at risk from air pollution in climate action plans.

Political Lobbying and Advocacy Campaigns – COVID-19. The results of this survey (2,400+ respondents) acted as the basis for a briefing to then Minister for Health Simon Harris, and a briefing to the Special Oireachtas Committee on Covid-19 Response and relevant opposition spokespersons. As a result of this outreach, we met with outgoing Minister for Health, Simon Harris, and then Green Party spokesperson for health Ossian Smyth to discuss the new coalition's asthma and COVID-19 policies. We also engaged with all major opposition parties, with a particular focus on health spokespersons and those who had supported our #AsthmaMatters general election manifesto, to brief them on the hopes of people with asthma and their carers for the 33rd Dáil. In addition, throughout the pandemic, the organisation established open lines of communication with relevant COVID-19 response teams in the HSE and Department of Health to ensure the needs and concerns of people with asthma were reflected in response planning.

ASTHMA SOCIETY OF IRELAND
DIRECTORS' REPORT (continued)
for the year ended 31 December 2020

ACHIEVEMENTS AND PERFORMANCE (Continued)

Advocacy and Behaviour Change Campaigns – Clean Air Children’s Activities. In February 2021, the Asthma Society launched its #OwnOurAir Clean Air Schools Competition, kindly supported by the ESB Group’s Energy for Generations Fund, inviting secondary school students to take an action against air pollution, document the action, and share on social media. The competition was highlighted on a dedicated section of asthma.ie, offering art activities for children of all ages to undertake while in lockdown. Classroom activity resources, including an 11-page lesson plan on asthma and air pollution, were developed and distributed and promoted on RTE’s Home School Hub website.

Advocacy and Behaviour Change Campaigns – Clean Air Research and Political Engagement. In September 2020, the Asthma Society launched research, conducted on its behalf by UCC Centre for Law and the Environment, which examined the most appropriate action for government to protect Irish residents from the effects of smoky fuels on their health. We called for the continual extension of the smoky coal ban as laid out in the Programme for Government, along with prohibition of the sale and use of other smoky fuels, which can be equally harmful to health. Oireachtas members were sent a substantive political briefing by the Asthma Society highlighting the research findings, and a briefing took place with the Department of the Environment, Climate and Communications.

Advocacy and Behaviour Change Campaigns – Clean Air Partnerships. The Asthma Society also joined two large scale air quality projects: Clean Air Together, led by An Taisce and the Environmental Protection Agency (EPA) and the LIFE Emerald Project, also led by the EPA.

Political Lobbying and Advocacy Campaigns – Pre-Budget Submission. In September 2020, we launched our Pre-Budget Submission calling on the government to introduce universal full subsidisation of asthma medications, expand the national fund for severe asthma medication, fund the extension of the current asthma management programme for all people with asthma, increase the number of registered Advanced Nurse Practitioners to meet 2% Department of Health guidelines and provide the Asthma Society with annual core funding. The pre-budget submission was made to the Department of Health.

Patient Representation. The Society participates in a number of key working groups to represent people with asthma in the wider healthcare policy landscape. These include the National Clinical Programme for Asthma, the Tobacco and e-Cigarettes Programme, the Irish Health Alliance at national level and the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) Global Allergy & Asthma Patient Platform at international level. A key undertaking as our role on the National Programme for Asthma in 2020 was our contribution in the drafting of the HSE’s Asthma Model of Care. ASI CEO Sarah O’Connor sits on the Sláintecare Advisory Council and on the Board of Irish Platform for Patient Organisations, Science and Industry (IPPOSI).

Patient Voice. The Asthma Society, as a patient representative organisation, ensures that the voice of the patient is not only heard, but also embedded into the foundation of the organisation. One stand-out piece of patient engagement was our COVID-19 survey – 2,400+ respondents – which investigated concerns and needs of people with asthma and their carers with regard to COVID-19. The results of this survey acted as the basis for a meeting with and briefing to then Minister for Health Simon Harris, and a written briefing to the Special Oireachtas Committee on COVID-19 Response and relevant opposition spokespersons.

Furthermore, as part of our COVID-19 response efforts, the organisation developed internal processes through which anonymised data charting trends in concerns and queries of patients using our support services were directly informing and shaping our communications and advocacy work. A significant element of the advocacy work was ongoing communication with relevant HSE actors and the National Clinical Respiratory Programme, to ensure asthma patients’ concerns regarding COVID-19 and government regulations were understood and formed part of HSE’s response.

Additionally, the organisation supported pharmaceutical company Novartis to engage patients with moderate to severe asthma in an advisory panel seeking attitudinal and behavioural insights into asthma medication use, including obstacles to maintaining compliance.

ASTHMA SOCIETY OF IRELAND
DIRECTORS' REPORT (continued)
for the year ended 31 December 2020

ACHIEVEMENTS AND PERFORMANCE (Continued)

2. We Support with Services - Patient Services Programmes

Evidence Based and Patient Friendly Advice re. Asthma and COPD During COVID-19 - Key to supporting patients during COVID-19 was the development of an Asthma COVID-19 response team. This comprised of staff triaging and managing calls, our Advocacy and Research Manager, Advocacy Officer, CEO, Communications Officer and our Medical Advisory Board, who all worked tirelessly to ensure we had accurate information, advice and recommendations in relation to asthma and COVID-19 on our website and social media. The Society also received considerable support from the National Clinical Programme for Asthma in endorsing these materials.

The team worked to develop evidence-based, patient friendly online and print resources to provide the respiratory-specific resources patients and healthcare professionals needed. These were not only foundational in terms of the work of our Adviceline and Beating Breathlessness teams, but also for our Adviceline triage team and our communications efforts. Some key examples included:

- Creation and updates of COVID Resource section on asthma.ie, focusing on tips on how to manage asthma and stay well during the COVID-19 pandemic.
- Creation of Asthma & COPD support materials “Staying well – Advice and Information for Asthma and COPD Patients During Coronavirus”
- Creation of “Cocooning from Coronavirus – Home Support Leaflet for People with COPD”
- Guidance on wearing face coverings
- Guidance on visiting and receiving visitors
- Moving Outside the Home: Cocooning Checklist
- Creation of a ‘Medically Vulnerable Person Lives Here’ graphic
- Creation of a graphic to explain symptoms across asthma/COPD/flu/hayfever and COVID-19

National Asthma and Chronic Obstructive Pulmonary Disease (COPD) Adviceline - This is the only such free service available to people with asthma and COPD in Ireland. It provides up to date, expert information and advice from asthma and COPD specialist nurses. The Asthma and COPD Adviceline is a collaboration between ASI, COPD Support Ireland and the HSE.

The COVID-19 pandemic contributed to a dramatic spike in Adviceline calls during Q1 and Q2 2020. In 2020, the Adviceline handled 6,816 incoming support requests - including triaged calls, Facebook and email queries – this was up from 714 incoming support requests in 2019. This influx on incoming support requests and the corresponding increase in nurse appointments necessitated up to 5 internal staff and 2 external HSE staff members being re-deployed to manage the volume of calls and support requests from March to September 2020.

The Adviceline nurse team provided 4,416 appointments in total - 3,853 asthma nurse appointments and 563 COPD appointments in 2020. The 3,853 asthma appointments was a marked increase on the previous year (2019: 2,977) and the Society has a service growth strategy in place to build on this in future years.

Nationwide nurse-led Asthma in the Pharmacy Clinics – Our ‘Asthma in the Pharmacy’ programme, supported by GSK, allows patients or their carers to meet an Asthma Society respiratory nurse for a private consultation at their local pharmacy. A total of 17 Asthma in the Pharmacy days were held in early 2020, prior to the pandemic guidelines. The Society plans to assess the potential impact of the Pharmacy Clinic programme in Q4 2021 as part of its services for patients and will analyse if any digital conversions may support future rollout of this programme.

New Beating Breathlessness Nurse-Led WhatsApp Service - The Asthma Society launched their Sláintecare Integration Fund sponsored, nurse-led Asthma & COPD WhatsApp messaging service on World Asthma Day in May 2020. Users receive comfort and reassurance that they are being listened to and given time and attention from HCP free of charge in the comfort of their own home. The nurse-led service allows patients with asthma and/or COPD, and their family and carers, to confidentially message a respiratory nurse about all aspects of their disease management.

The nurses had provided support to 610 service users by December 2020, which totalled 5064 patient chats with the nurse. 43% gave a score of 3 or less in rating their asthma management confidence prior to using the service.

ASTHMA SOCIETY OF IRELAND

DIRECTORS' REPORT (continued) for the year ended 31 December 2020

ACHIEVEMENTS AND PERFORMANCE (Continued)

This rose to 68% of users rating their asthma management (4 or higher) after using the service, indicating it had improved their confidence in managing their condition. 83% of users surveyed gave a recommender rating of 4 or 5 – they would recommend this service to a friend or family member.

Self-Management Master Classes - The Sláintecare Integration Fund also sponsored the rollout of two self-management masterclasses, where asthma and COPD patients and their carers were provided with advice and education to support them in staying well during winter/COVID-19 – inhaler use/compliance, flu & pneumococcal vaccination & the importance of completing an Asthma Action Plan with a healthcare professional. There were 277 and 116 people registered respectively. 94% of asthma attendees and 93% of COPD attendees reflected that they had a clearer understanding of what to do when their/their family member's symptoms worsen, and when it is necessary to take action after attending the event.

Asthma Education Inclusion Projects - The Asthma Society, collaborated with HSE Social Inclusion in the South East Community Healthcare and Pavee Point Traveller and Roma Centre, to develop literacy friendly and culturally appropriate information resources and videos for the Roma, Refugees, People Seeking International Protection Community and the Traveller Community. These resources aim to equip intercultural health workers with the skills and knowledge to be able to communicate key messages relating to asthma to their client groups. These resources can also be utilised by the communities and healthcare professionals.

Programme participants identified the need for picture-based and video asthma education leaflets and the translation of information resources to enable them to disseminate asthma education to the communities in which they work. This work was undertaken extensively in 2020 and the following resources developed were translated into English, Romanian, French, Georgian, Brazilian Portuguese, Arabic, Iberian Portuguese & Pashto and available were launched in February 2021 and are available at asthma.ie and through the Asthma Society's Youtube channel.

Special Respiratory Supports - Between May and September 2020, the Asthma Society of Ireland in partnership with Cystic Fibrosis Ireland and the Irish Lung Fibrosis Association (supported by Community Foundation and Bank of Ireland) developed and delivered health and wellbeing programme. This programme supported people in Ireland with respiratory conditions and their families, as the patient engagement research highlighted a need to manage heightened levels of anxiety or stress as a result of COVID-19. The programme included a joint respiratory webinar to inform patients about how to keep well during the pandemic, reassuring patients and including perspectives from medical and nursing professionals working on the frontline of COVID-19, as well as respiratory patient advocates. 480 people registered for the webinar, 213 of which had an underlying respiratory condition.

The three respiratory charities hosted a Facebook Live mindfulness event delivered by Maria Love, Senior Social Work Practitioner at the Mater Hospital. The mindfulness session had over 1.7K views and it reached 10,060 people. The three respiratory charities also collaborated by delivering a Facebook Live Yoga Session & a webinar 'Adapting to the new normal: A webinar on returning to school' whereby 160 people registered for the webinar.

In total, it is estimated that approximately 4050 people benefitted directly from the delivery of this programme of supports for respiratory patients.

Schools Programme The Society continued its Asthma Friendly Schools campaign in 2020. As part of the programme, 575 primary schools across 7 CHO areas in Ireland were sent a school pack with helpful asthma resources - Asthma Friendly Schools Book, Five Step Rule Poster, Asthma Attack Cards, Asthma Action Plans, Kids Activity Book & an Asthma Trigger Audit.

The Society developed a new proposal for a Safe Schools Programme and applied for funding under the HSE Lottery Fund in late 2020 and was successful for rollout in Q1/Q2 2021. The new programme will have a stronger focus on asthma deaths prevention – funding for 30 schools to undertake PHECC training, ultimately registering those organisations for asthma inhalers in case of emergency.

Asthma HealthPacks – In collaboration with CarePlus Pharmacies, the Asthma Society provided free COVID-19 Asthma HealthPacks to support people with asthma during the COVID-19 pandemic. An estimated 3000 packs were disseminated, which people with asthma and their families/friends were available, for free, throughout 64 Careplus pharmacies nationwide, containing information and support to help people stay safe during this COVID-19 pandemic. These packs also prompted an engagement between patient and pharmacist on asthma management.

ASTHMA SOCIETY OF IRELAND
DIRECTORS' REPORT (continued)
for the year ended 31 December 2020

ACHIEVEMENTS AND PERFORMANCE (Continued)

These packs consist of patient education materials on asthma or COPD and COVID-19, as well as information on managing asthma in children, general asthma management, dealing with an asthma attack (the 5 Step Rule), and details of key services offered by the Asthma Society during this pandemic.

3. We Communicate about Asthma

Award-Winning Campaign

SafetyCare Awareness Campaign – Irish Healthcare Award. The Society's first ever SafetyCare campaign focussed on creating behaviour change around a recurring and dangerous asthma management problem – over-reliance on SABA to manage asthma. **The campaign aimed:**

- To raise awareness about SABA overuse and highlight its association with asthma related death
- To educate people on what SABA inhalers do and when they should be used
- To educate people on how ICS inhalers work and the differentiate them from SABA inhalers
- To encourage people to use an Asthma Action Plan to understand if they are overusing their SABA

The campaign, supported by AstraZeneca, secured front page coverage on the Irish Independent and Independent.ie and was covered in the Irish Times and Irish Examiner, among other national and regional print media, and on Virgin Media News, FM104 and NewsTalk and regional radio across the country. The Facebook Live event with expert respiratory consultant Dr. Marcus Butler was viewed 19,300 times and social media posts reached over 150,000 people. The Ruepoint assessment of the campaign indicated it had a reach of 26 million.

This engagement was converted into considerable patient action – the Asthma Society experienced a 30% increase in advice line calls in February compared to January of the same year. There were **2,090 visits** to our dedicated asthma.ie campaign page, where 777 asthma action plans were downloaded through the campaign in February 2020.

The campaign won an Irish Healthcare Award in 2020 for Patient Lifestyle Education Project of the Year.

Our COVID-19 Communications Strategy – As per sections above, the Asthma Society created an integrated programme of supports and engagements across our services, our advocacy engagements, our research and learning. All these integrated, whole-organisation approach project was funnelled into our communications strategy and tactical planning. Every element we worked on to support patients had a corresponding communications push-out to our members, asthma and COPD patients and their families, healthcare professionals and members of the public. The scale of communications outreach was bigger and always-on, and the reach and engagement with our awareness-building and reassurance-providing work was also very substantially increased on previous years. We believe we were deeply relevant and impactful.

Some achievements in our outward facing awareness pillar can be seen in the following results:

Asthma Society Website – asthma.ie – The site saw 149.38% increase in visits to asthma.ie compared to same period in the 2019 (total page visits of 928,338 vs 372,254), which included 790,906 unique page views. There were 249,106 visits to the COVID-19 FAQ page (26% of all website visits), which included 223,992 unique page views. From March to September 2020, website visitors were spending over five minutes on the site on average.

Website visits were converted into key healthcare actions and behaviour change moments for patients, as evidenced by the following:

Asthma Action Plan downloads – There were 18,762 Asthma Action Plans downloaded from the website in 2020. There were 71,400 views of the Asthma Action Plan through Facebook in 2020.

5 Step Rule views – Our 5 Step Rule was viewed as a graphic and video on Youtube, Facebook, and on our website a total of 55,158 times. This is up from 6,621 views in 2019.

Inhaler Technique videos – Our inhaler technique videos were viewed 32,785 times in 2020. This is up 21,131 views in 2019.

ASTHMA SOCIETY OF IRELAND
DIRECTORS' REPORT (continued)
for the year ended 31 December 2020

ACHIEVEMENTS AND PERFORMANCE (Continued)

Asthma.ie Kids Corner – We created a new Kids Corner on asthma.ie, gathering all our child-friendly materials, leaflets and activities for children in one easy to find location. A total of 13,528 visit to this site saw patients and carers download our children's activity pack, the Control Your Asthma booklet, view specific inhaler technique videos appropriate to children, and key Back2School materials.

Facebook Live Broadcasts – The Asthma Society began to utilise Facebook Live Broadcasts in a new way in 2020. An early February Facebook Live Broadcast with Dr. Marcus Butler about our Safetycare on SABA over-reliance, re-shared during the pandemic, was viewed 19,400 times.

Every time we updated our COVID-19 FAQ document or we experiencing a new patient need for reassurance and advice from March-September 2020, we did a Facebook Live to inform and guide – in particular, we believe Facebook Live broadcasts ensured that many patients experiencing health literacy challenges were supported as best possible, and had many of their pressing queries answered through this format. In total, we created 14 patient-centred information Facebook Live Broadcasts to support patients and carers through COVID-19. These were undertaken by our CEO, our Beating Breathlessness nurse, Ruth Morrow, and our Medical Director, Dr. Marcus Butler, and received huge engagement. Each Facebook Live broadcast was followed by increased utilisation of our services and website.

Campaign Highlights

Asthma Awareness Week – The Asthma Society launched its Beating Breathlessness nurse-led WhatsApp messaging service during Asthma Awareness Week and also ran its 10 Million Steps for Asthma fundraising campaign. The aims of the campaign were diverse:

- To promote the Asthma Society's new Beating Breathlessness WhatsApp patient support service and encourage people with asthma and COPD to avail of this free service
- To encourage people to properly manage their asthma during COVID-19 and educate them on why it is so important to do so
- To help alleviate the anxiety felt by people with respiratory conditions during COVID-19
- To raise much needed funds for the Asthma Society to allow us to continue our vital work in improving the lives of people with asthma
- To encourage people to use the Asthma Society's existing free Asthma and COPD Adviceline service

The campaign featured on RTE 9 O'clock News, Morning Ireland, and RTE's Home School Hub website and was featured extensively on print media including the Irish Independent, the Sunday Business Post and the Irish Times – overall it achieved total potential reach of 22,188,386 (through PR, digital and advertising). Over 150 people used the Beating Breathlessness service in its first month.

The Minister for Health, Simon Harris, met with the Society during Asthma Awareness Week to launch its strategy, and created a video to support its fundraising campaign. An Taoiseach, Leo Varadkar, supported the fundraising campaign.

The 10 Million Steps for Asthma fundraiser raised €11,250.

The campaign was kindly supported by Boots Ireland, GSK Ireland and Novartis Ireland. The campaign was short-listed for a PRCA PR Award for Best Communications Campaign by a Not-for-Profit Organisation.

Back2School / Back2Work / Back2Basics Campaign – Responding to patient requests for support and advice, the Society created a triple-support programme for September 2020 encompassing patient supports and advice, digital asset creation and media engagement. It included a Back2Basics Facebook Live Broadcast on asthma management and a Back2Work Checklist, which were heavily requested by patients and which garnered extensive usage and positive feedback.

The Society also ran an extensive Back2School campaign which included the creation of a COVID-19-relevant Back2School checklist and a Back2School webinar featuring Professor Des Cox and our Beating Breathlessness nurse, Ruth Morrow. 292 parents and carers registered for this event.

ASTHMA SOCIETY OF IRELAND

DIRECTORS' REPORT (continued) for the year ended 31 December 2020

ACHIEVEMENTS AND PERFORMANCE (Continued)

Our Hayfever Campaign – This campaign, kindly supported by Dyson, achieved 49,023 visits in 2020, a 17% increase in Pollen Tracker users in 2020 compared to 2019 and had a reach of over 3 million, with 59 pieces of media coverage, including the RTE Guide, Irish Examiner and The Hard Shoulder on Newstalk. The Know Your Symptoms graphic, communicating the difference between asthma/COPD/hayfever/flu and COVID-19 symptoms, reached 38,000 people on Facebook and was shared 631 times. 500 people completed our hayfever survey.

Winter Wellness – This campaign, supported by MSD Ireland, aimed to encourage people with asthma and COPD to avail of their vaccinations, which was of particular importance during the COVID-19 pandemic, and to encourage people with asthma and COPD to be vigilant with their asthma/COPD management during the Winter months and to get an Asthma Action Plan/COPD Management Plan in place, particularly in relation to weather triggers. The campaign featured on RTE's Today Show with Maura and Daithi and the campaign had a reach of 792,457. The Winter Wellness page on asthma.ie had 1,527 and people spent on average 3m 15s on the page. 140 people registered for the Asthma Winter Wellness webinar and 116 for the COPD Winter Wellness webinar and 119 and 63 attended respectively.

Day-to-Day Awareness Building - The Society relied on newsletters, e-zines, practical tips and advice via social media, web to communicate regularly and to replace our traditional face-to-face interactions and effectively with the public, which all drove increased engagement levels than seen in previous years.

4. We Learn Together

Research – Safetycare - A piece of research conducted by HMR into the usage rates of Salbutamol (reliever inhaler) was undertaken to assess the extent of over reliance on reliever inhalers among people with asthma in the Irish population. The findings of this research formed part of a patient awareness and education campaign to raise awareness among people with asthma and their carers about appropriate use of reliever inhalers and the health risks associated with overreliance on reliever inhalers.

UCC Research - In September 2020, the Asthma Society launched research, conducted on its behalf by UCC Centre for Law and the Environment, which examined the most appropriate action for government to protect Irish residents from the effects of smoky fuels on their health. We called for the continual extension of the smoky coal ban as laid out in the Programme for Government, along with prohibition of the sale and use of other smoky fuels, which can be equally harmful to health. Oireachtas members were sent a substantive political briefing by the Asthma Society highlighting the research findings, and a briefing took place with the Department of the Environment, Climate and Communications.

Severe Asthma – A literature review on severe asthma was undertaken internally to inform our future work programme on this issue. This literature review will act as the basis for the comprehensive research project to be undertaken in 2021-22.

Asthma Deaths - Due to COVID-19 restrictions, our asthma deaths panel was put on hold. To ensure work continued to be progressed, however, an analysis of CSO data on asthma deaths from 2010-2019 was conducted to inform the work of the organisation going forward.

ASTHMA SOCIETY OF IRELAND

DIRECTORS' REPORT (continued) for the year ended 31 December 2020

CORPORATE PARTNERS 2020

The Asthma Society would like to acknowledge the following corporate partners for their support for our work in 2020. Many of these partners worked with us to adapt original agreed programmes of work to meet the changing needs of patients through 2020. Other partners supported us for the first time in 2020. We thank all these partners for their support.

Astra Zeneca
Bank of Ireland (through the Community Foundation of Ireland)
Boots Ireland
Cara Pharmacy
Careplus
Citrix
CPL
Dyson
Genomics Medicine Ireland (now Genuity Science)
GSK
Malones of Dublin
MSD Ireland
Musgraves
Novartis
Orion Pharmacy
Salutem Insights
Stryker
Tesco
Teva Pharmaceuticals
The Allergy Clinic
United Drug

TRUST AND FOUNDATION SUPPORT 2020

The Asthma Society would like to thank the following Trusts and Foundations for their support for our work in 2020:

Community Foundation of Ireland
ESB – Funding for Generations
Hospital Saturday Fund
HSE Lottery Fund

STRUCTURE, GOVERNANCE AND MANAGEMENT

GOOD GOVERNANCE AND TRANSPARENCY

The Asthma Society of Ireland is fully compliant with "The Charities Governance Code" issued by the Charities Regulatory Authority in Ireland which was introduced in November 2018. We achieved this compliance by the 2020 deadline, when the Charities Code Governance Compliance Record was presented to the Board in December 2020.

Our accounts and financial reports are compliant with Statement of Recommended Practice (SORP). The Society undertook an external audit of its HR and implemented a number of changes identified within that audit.

Our nurse-led services are compliant with the Code of Professional Conduct and Ethics for Registered Nurses and Registered Midwives and our Asthma Adviceline service is fully accredited by the Helplines Partnership (this accreditation was renewed for three years in early 2019).

To actively demonstrate openness, transparency and integrity to our beneficiaries and donors, the Asthma Society aims to operate to the Triple Lock Standards of transparent reporting, good fundraising and governance. The Asthma Society is working towards final adherence to this sectoral standard and formally submitted documentation for Triple Lock accreditation in late 2021.

ASTHMA SOCIETY OF IRELAND

DIRECTORS' REPORT (continued) for the year ended 31 December 2020

The Society published its Five-Year Strategy in May 2020, *Stopping Asthma Deaths in Ireland, 2020-2025*, with an ultimate goal of ending asthma deaths by 2030.

CONSTITUTION

The Society held an EGM in Q3 2020, updating its membership and its Memorandum and Articles of Association to meet with best practice corporate governance standards, as set out by the CRA under its guidelines.

The charity was founded in 1973 and registered as a company limited by guarantee in 1976. The liability of members is limited as defined in the Company's Constitution and shall not exceed €5 in the event of a winding up or dissolution of the Company.

The principal office of the Society is 3rd Floor, 42 - 43 Amiens Street, Dublin 1. The Company's registered number is 57125, its Charities Regulator number is 20010270 and its charity registration number is CHY 6100. Governance and management structures are set out in the Constitution.

The Society is governed by its Board of Directors, which includes representation from a broad range of stakeholders including people with asthma, the medical profession, communications and financial practitioners. The Directors are appointed to terms of office that comply with the Constitution of the Society. The term of office is generally three years, but Directors may be reappointed to serve two further terms.

The Board of Directors met ten times in 2020, up from six times in 2019, this increase reflecting the need to adapt the organisation's activities and operations as a result of the COVID-19 pandemic. The Directors have responsibility for appointing the Chief Executive Officer who has decision making powers in relation to a range of day to day decisions, and appointed an Interim Chief Executive Officer, Emily Blennerhassett, who served from August 2020 to March 2021.

The Board is supported by its Medical Advisory Group (MAG), its Audit, Risk and Finance Committee (ARFC) and its Fundraising and Communications Committee (FCC). The Society also benefits from occasional supports offered by its Independent Air Advisory Panel, formed in 2019, to support its work on its #OwnOurAir campaign – this panel is made up of highly qualified scientists and researchers with expertise in air quality and its impact on our environment and our health.

FUTURE DEVELOPMENTS

Through-out 2020, the Asthma Society, in collaboration with Pavee Point and the HSE Social Inclusion Office, developed culturally appropriate information resources and videos for Traveller and Roma and people seeking international assistance communities and will launch these materials in February 2021.

ASI adapted the Asthma Friendly Schools programme and ran a pilot programme called Asthma Safe Schools in early 2021 (following successful funding from four CHOs in Q4 2020). The Society is seeking to expand the number of schools participating in the Safe Schools programme in future years by generating additional statutory funding support for this programme.

The Asthma Society will run a second Safetycare campaign in 2021, aiming to build patient and healthcare professional awareness of the need to highlight oral corticosteroid usage in patients, to improve asthma management and reduce the burden of side effects. This campaign is part of the Society's work to eliminate asthma deaths in Ireland.

In Q3 2021, the Asthma Society recruited a Development and Fundraising Manager to further develop income streams, its engagement with membership and possible partnerships with corporate partners surrounding wellness programmes and charity partnerships. These income streams are of considerable future importance with the wind-down of the Superdraw.

ASTHMA SOCIETY OF IRELAND

DIRECTORS' REPORT (continued) for the year ended 31 December 2020

Impact of COVID-19

Originally, 2020 was expected to be a financially stable year with the Board predicting a modest surplus at year end. While the Society returned a deficit for the year, this was kept as small as possible with cost-cutting measures and considerable fundraising efforts with existing statutory and corporate partners and new income from Trusts and Foundations.

The Society monitored performance against its objectives during 2020 and 2021. Due to the impact of COVID-19 some programmes were delayed or cancelled but the majority of planned activities either went ahead as normal or were redeveloped into an 'online or virtual' format, or very considerably expanded to meet patient needs. A restructuring of the team in Q2 2021 was an outcome that the Society had hoped to avoid but was necessary given the financial impact of COVID-19 across all society, including charity fundraising in particular.

A collaborative approach across all programmatic areas during 2020 and into 2021 has led to innovative partnerships with other charities and organisations to deliver excellent services and programmes, building the Society's network and impact as a result. In particular, these included: COPD Support Ireland, Cystic Fibrosis Ireland, and the Irish Lung Fibrosis organisation.

The Society is assessing its ongoing programmatic mix in late 2021 and prioritising to ensure it has sufficient resourcing and funding to run the most impactful and cost effective supports and interventions it can offer to patients and their carers. The "long tail" of the financial impact of COVID-19 into late 2021 is an important area of focus and all fundraising initiatives are aimed at creating the diverse mixed and secure funding that the Society needs going forward.

PRINCIPAL RISKS AND UNCERTAINTIES

The Board of Directors has assessed the major risks to which the Society is exposed.

Risk management approach:

The Society maintains a risk appetite document and a risk register. The Audit, Risk and Finance Committee ("ARFC") are responsible for the oversight of the maintenance of both. As of June 2021, the risk register was in the process of being updated and the risk register is a standing item on all ARFC agendas. A whole of organisation and always-on approach will be applied to risk in the Society.

The principal risks and uncertainties facing the Society are as follows:

Maintaining financial stability and sustainability:

The work of the Society requires funding. Accordingly, the main risk facing the Society in achieving its strategy is its ability to maintain its income as seen in 2018 and 2019, and to grow income where required to fund new initiatives.

The Society prepares budgets and cash flow forecasts, which are reviewed on a regular basis in conjunction with its management accounts. Depending on the results, the Directors, where necessary, take appropriate action as was the case in 2020 and into 2021. Monthly accounts and the related analysis and controls are a key output for the Society. The appointment of a new Finance and Compliance Manager in August 2021 has brought about change to provide greater insight into the long-term financial management of the Society for the Board and CEO. This involves an earlier annual budgeting process for 2022 and a five-year costed programme of work.

The Society is developing an updated long-term strategy to grow income, with a particular focus on unrestricted corporate funding and ongoing member donations. Parallel to this, the Society is also aiming to broaden the statutory funding available to the organisation.

Like many organisations, the Society was affected by the COVID-19 pandemic in 2020 and, to a deeper degree, into 2021 as cost-cutting measures had already been undertaken while one-off costs like redundancies were also incurred. While certain income streams have been negatively impacted, the Society is working in a disciplined way to look at funding from a "whole organisation" approach to reduce reliance on single sources of programme funding and to ensure that an appropriate level of financial scrutiny is applied to smaller programmes to achieve maximum patient impact within the limited resources available.

ASTHMA SOCIETY OF IRELAND
DIRECTORS' REPORT (continued)
for the year ended 31 December 2020

PRINCIPAL RISKS AND UNCERTAINTIES (continued)

Staff recruitment and retention:

The Society achieves its results through its CEO and staff. If the Society is to achieve its objectives, the CEO and other staff must build close and effective relationships where they can deliver on the Society's mission together. The ability to attract and retain appropriate staff was particularly challenging from late 2020 into mid-2021. The team restructuring and retention challenge meant that continuity and organisational memory was affected from 2020 into 2021. While all services and programmes continued to be implemented to a high standard, the restructuring and staff handovers involved in 2021 had an impact on the Society's ability to implement its fundraising strategy until Q3 2021.

The Directors are satisfied that there are adequate staff recruitment and retention policies in place to mitigate this risk going forward and that all staff receive ongoing training and support to fulfil their roles. A major emphasis was placed in 2020-21 on appointing department heads in order to create an effective management structure, which has played a key role in the Society's expanded and impactful service delivery during the COVID-19 pandemic and its resilience in responding to financial challenges posed by the pandemic. Additionally, a focus is being put on forensically matching resourcing and budgets to programme commitments, targets and objectives to make all projects undertaken realistic and achievable within budget.

Internal controls:

The Directors are satisfied that the system of internal controls and procedures provides reasonable assurance of the safeguarding of assets, the maintenance of proper accounting records, and the reliability of the financial information, particularly in light of changes to the staffing structure within the finance section.

Medical oversight:

The Society seeks to ensure that the advice it offers to patients and their carers is up to date and appropriate. Accordingly, the Society has access to a Medical Advisory Group to assess and guide the Society's approach to minimise the risk that our stakeholders receive advice that is not best practice. The Society, in particular, also gains extensive insight, technical advice and guidance from its Medical Director, Dr. Marcus Butler.

ACCOUNTING RECORDS

The measures taken by the Directors to ensure compliance with the requirements of Sections 281 to 285 of the Companies Act 2014, with regard to the keeping of accounting records, are the employment of appropriately qualified accounting personnel and the maintenance of computerised accounting systems. The company's accounting records are maintained at the company's registered office.

POST BALANCE SHEET EVENTS

There have been no events since the balance sheet date, which necessitate revision of the figures included in the financial statements or require inclusion of a note thereto.

POLITICAL CONTRIBUTIONS

There were no political contributions which require disclosure under the Electoral Act 1997.

ASTHMA SOCIETY OF IRELAND

**DIRECTORS' REPORT (continued)
for the year ended 31 December 2020**


STATEMENT ON RELEVANT AUDIT INFORMATION

In the case of each of the persons who are directors at the time this report is approved in accordance with Section 332 of the Companies Act 2014:

- so far as each director is aware, there is no relevant audit information of which the company's statutory auditors are unaware, and
- each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's statutory auditors are aware of that information.

INDEPENDENT AUDITOR

In accordance with Section 382(2) of the Companies Act 2014, the auditors, Mazars, will continue in office.



Ciaran McGloin
Director



David Clancy
Director

Date: 26 October 2021

ASTHMA SOCIETY OF IRELAND

**DIRECTORS' RESPONSIBILITIES STATEMENT
for the year ended 31 December 2020**

The Directors are responsible for preparing the Directors' report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have elected to prepare the financial statements in accordance with the Companies Act 2014, FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' issued by the Financial Reporting Council and the Statement of Recommended Practice (Charities SORP (FRS 102)), issued by the Charity Commission for England and Wales, the Charity Commission for Northern Ireland and the Office of the Scottish Charity Regulator. Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the Company as at the end of the financial year, and the results of the Company for the financial year, and otherwise comply with the Companies Act 2014.


In preparing those financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The Directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and income and expenditure of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in Ireland governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

On behalf of the Board of Directors


Ciaran McGloin
Director


David Clancy
Director

Date: 26 October 2021

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF
ASTHMA SOCIETY OF IRELAND**

Report on the audit of the financial statements

Opinion

We have audited the financial statements of Asthma Society of Ireland ('the Company'), which comprise the Statement of Financial Activities, the Balance Sheet, Statement of Cash Flows, and notes to the Company financial statements, including the summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish law and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland.

In our opinion, the accompanying financial statements:

- give a true and fair view of the assets, liabilities and financial position of the Company as at 31 December 2020, and of its results for the year then ended;
- have been properly prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report.

We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of matter – Impact of COVID-19

In forming our opinion on the Company's financial statements we draw your attention to the impact of Covid-19 on the activities of the Company as detailed under the Business Review and Financial Results in the Directors' Report and in note 3(a), Going Concern. Our opinion is not qualified in this regard.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The directors are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2014

In our opinion, based on the work undertaken in the course of the audit, we report that:

- the information given in the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements;
- the directors' report has been prepared in accordance with applicable legal requirements;
- the accounting records of the Company were sufficient to permit the financial statements to be readily and properly audited; and
- the financial statements are in agreement with the accounting records.

We have obtained all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of our audit.

Matters on which we are required to report by exception

Based on the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified any material misstatements in the directors' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the requirements of any of Sections 305 to 312 of the Act, which relate to disclosures of directors' remuneration and transactions are not complied with by the Company. We have nothing to report in this regard.

Respective responsibilities

Responsibilities of directors for the financial statements

As explained more fully in the directors' responsibilities statement out on page 16, the directors are responsible for the preparation of the financial statements in accordance with the applicable financial reporting framework that give a true and fair view, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements


Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that

includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Irish Auditing and Accounting Supervisory Authority's website at: http://www.iaasa.ie/getmedia/b2389013-1cf6-458b-9b8f-a98202dc9c3a/Description_of_auditors_responsibilities_for_audit.pdf. This description forms part of our auditor's report.

The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the Company's members, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.



Aedín Morkan
for and on behalf of Mazars
Chartered Accountants & Statutory Audit Firm
Harcourt Centre, Block 3
Harcourt Road
Dublin 2

Date: 27 October 2021

ASTHMA SOCIETY OF IRELAND

**STATEMENT OF FINANCIAL ACTIVITIES (Includes income and expenditure account)
for the year ended 31 December 2020**

		Unrestricted funds 2020 €	Restricted funds 2020 €	Total funds 2020 €	Total funds 2019 €
Income from:					
Donations and legacies	4	502,067	251,208	753,275	742,906
Charitable activities	5	30,704	436,054	466,758	326,410
Investments	6	46	-	46	47
Total income		532,817	687,262	1,220,079	1,069,363
Expenditure on:					
Raising funds	7	269,006	17,671	286,677	346,765
Charitable activities	8	343,721	676,028	1,019,749	779,969
Total expenditure		612,727	693,699	1,306,426	1,126,734
Net expenditure		(79,910)	(6,437)	(86,347)	(57,371)
Transfer of funds		4,173	(4,173)	-	-
Net movement in funds		(75,737)	(10,610)	(86,347)	(57,371)
Reconciliation of funds:					
Total funds at 1 January	19, 20	358,738	79,691	438,429	495,800
Total funds at 31 December	19, 20	283,001	69,081	352,082	438,429

There were no other recognised gains or losses in the current or prior year other than those included in the Statement of Financial Activities. All income and expenditure derive from continuing activities. The notes on pages 23 to 38 form part of these financial statements.

ASTHMA SOCIETY OF IRELAND

BALANCE SHEET
as at 31 December 2020

	Note	2020 €	2019 €
FIXED ASSETS			
Tangible assets	14	29,906	-
CURRENT ASSETS			
Stocks	15	1,212	3,674
Debtors	16	60,100	122,865
Cash and cash equivalents		<u>405,186</u>	<u>551,949</u>
		466,498	678,488
CREDITORS			
Amounts falling due within one year	17	<u>(144,322)</u>	<u>(240,059)</u>
NET CURRENT ASSETS		<u>322,176</u>	<u>438,429</u>
TOTAL NET ASSETS		<u>352,082</u>	<u>438,429</u>
FUNDS			
Unrestricted funds	19, 20	283,001	358,738
Restricted funds	19, 20	<u>69,081</u>	<u>79,691</u>
TOTAL FUNDS		<u>352,082</u>	<u>438,429</u>

The financial statements were approved and authorised for issue by the Directors and signed on their behalf by:



Ciaran McGloin
Director



David Clancy
Director

Date: 26 October 2021

The notes on pages 23 to 38 form part of these financial statements.

ASTHMA SOCIETY OF IRELAND
STATEMENT OF CASH FLOWS
for the year ended 31 December 2020

	Note	2020 €	2019 €
Cash flows from operating activities			
Net expenditure for the year		(86,347)	(57,371)
Adjustments for:			
Depreciation of tangible fixed assets	14	2,642	918
Deposit interest income	6	(46)	(47)
Decrease / (increase) in debtors		62,765	(13,906)
Decrease in stocks		2,462	788
(Decrease) / increase in creditors		(95,737)	21,626
Net cash used by operating activities		(114,261)	(47,992)
Cash flows from investing activities			
Deposit interest income	6	46	47
Acquisition of tangible fixed assets	14	(32,548)	-
Net cash (used in) / provided by investing activities		(32,502)	47
Net decrease in cash and cash equivalents		(146,763)	(47,945)
Cash and cash equivalents at the start of the year		551,949	599,894
Cash and cash equivalents at the end of the year		405,186	551,949

The notes on pages 23 to 38 form part of these financial statements.

ASTHMA SOCIETY OF IRELAND

NOTES TO THE FINANCIAL STATEMENTS for the year ended 31 December 2020

1. GENERAL INFORMATION

Asthma Society of Ireland (“the Charity”) is a Company Limited by Guarantee incorporated in Ireland with a registered office at 3rd Floor, 42-43 Amiens Street, Dublin 1, Ireland and its company registration number is 57125.

These financial statements comprising the Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flows and the related notes constitute the financial statements of the Asthma Society of Ireland for the financial year ended 31 December 2020. The nature of the Charity’s operations and its principal activities are set out in the Directors’ Report on page 2.

Asthma Society of Ireland meets the definition of a public benefit entity under FRS 102.

Statement of compliance

The financial statements have been prepared in accordance with “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (FRS 102). The financial statements have also been prepared in accordance with the Statement of Recommended Practice (SORP) (FRS 102) “Accounting and Reporting by Charities”.

Currency

The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. ACCOUNTING POLICIES

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the financial statements.

2.1 Basis of preparation of financial statements

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention modified to include certain items at fair value. The financial reporting framework that has been applied in their preparation is the Companies Act 2014, FRS 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the Statement of Recommended Practice (Charities SORP (FRS102)) as published by the Charity Commission for England and Wales, the Charity Commission for Northern Ireland and the Office of the Scottish Charity Regulator which are recognised by the UK Financial Reporting Council (FRC) as the appropriate bodies to issue SORPs for the charity sector in the UK. Financial reporting in line with SORP is considered best practice for charities in Ireland.

The Directors consider that the adoption of the SORP requirements is the most appropriate accounting to properly reflect and disclose the activities of the organisation.

ASTHMA SOCIETY OF IRELAND

NOTES TO THE FINANCIAL STATEMENTS (continued) for the year ended 31 December 2020

2. ACCOUNTING POLICIES (continued)

2.2 Income

All income is recognised in the Statement of Financial Activities where there is entitlement, receipt is probable, and the amount can be measured with sufficient reliability. The following specific policies are applied to categories of income:

Donations and legacies: Voluntary income including donations, gifts and legacies are recognised where there is entitlement, receipt is probable, and the amount can be measured with sufficient reliability. Such income is only deferred when the donor specifies that the grant or donation must only be used in future accounting periods or the donors have imposed conditions which must be met before the Charity has unconditional entitlement.

Donations received from individuals and companies using online fundraising platforms to raise funds are recognised when the Charity already has an entitlement, it is probable that the donations will be received and it can be measured reliably.

Legacy income is recognised in the accounting period in which it is received or when it is probable that the legacy will be received and the value of the legacy can be measured reliably. In these circumstances, if the legacy income has been received post year end, and the personal representatives have agreed to the amount thereof prior to the year end, the income can be recognised.

Assets donated under bequests or otherwise are included in the Statement of Financial Activities at their value to the Charity on the date of receipt.

Income from Charitable Activities: Grants from public authorities and other agencies in Ireland are credited to the Statement of Financial Activities in the year to which they relate. Grants received towards capital expenditure are credited to the Statement of Financial Activities when received or receivable whichever is earlier. Grants are recognised when there is evidence of entitlement and their receipt is probable. Grant income is deferred where the Charity is restricted by specific performance related conditions that are evident in the grant agreement, where there is a specification of a time period that limits the Charity's ability to spend the grant until it has performed that activity related to the specified time period and when there are specific terms or conditions within the agreement that have not been met and are not within the control of the Charity.

Temporary Wage Subsidy Scheme (TWSS) income: Income received from the TWSS has been recognised in accordance with accounting for government grants in line with Charities SORP.

Fundraising income: Fundraising income is credited to the Statement of Financial Activities in the year in which it is receivable by the Charity.

Investment income: Income earned on funds held on deposit is treated as unrestricted income and is credited when earned. Interest received on the Charity's investments is recorded as income in the year in which it is earned under the effective interest rate method.

Deferred income: Deferred income consists of grants received in advance which will be recognised upon fulfilment of the related conditions.

ASTHMA SOCIETY OF IRELAND

NOTES TO THE FINANCIAL STATEMENTS (continued) for the year ended 31 December 2020

2. ACCOUNTING POLICIES (continued)

2.3 Expenditure

Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is reported as part of the expenditure to which it relates:

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities.

Charitable expenditure comprises those costs incurred by the Charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs arise from those functions that assist the work of the Charity but do not directly undertake charitable activities. Costs are charged to each service and activity in proportion to expenditure, which is considered to reflect estimated benefits received. Costs are not allocated to designated or fixed asset funds.

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the Charity and include the audit fees, costs of legal advice for Directors and costs linked to the strategic management of the Charity including the cost of Directors' meetings.

2.4 Fund accounting

Restricted funds

Restricted funds represent grants, donations and sponsorships received which can only be used for particular purposes specified by the donors or sponsorship programmes binding on the Directors. Such purposes are within the overall aims of the Charity.

Unrestricted funds

Unrestricted funds include general funds and designated funds and represent amounts which are expendable at the discretion of the Directors in furtherance of the objectives of the Charity. Such funds may be held in order to finance working capital or capital expenditure.

2.5 Tangible fixed assets and depreciation

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Fixtures and fittings	-	20% straight line
Website development	-	33% straight line
Computer equipment	-	33% straight line

The company's policy is to review the remaining useful economic lives and residual values of tangible fixed assets on an ongoing basis and to adjust the depreciation charge to reflect the remaining estimated useful economic life and residual value.

Fully depreciated tangible fixed assets are retained in the cost of tangible fixed assets and related accumulated depreciation until they are removed from service. In the case of disposals, assets and related depreciation are removed from the financial statements and the net amount, less proceeds from disposal, is charged or credited to the Statement of Financial Activities.

ASTHMA SOCIETY OF IRELAND

**NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2020**

2. ACCOUNTING POLICIES (continued)

2.6 Stocks

Stocks are valued at the lower of cost and net realisable value after provisions for obsolete and slow-moving stocks.

2.7 Trade and other debtors

Trade and other debtors are initially measured at cost, which is normally the transaction price, and are subsequently measured at amortised cost less impairment, where there is objective evidence of impairment.

2.8 Cash and cash equivalents

Cash and cash equivalents include cash on hand, demand deposits and other short-term highly liquid investments with original maturities of three months or less.

2.9 Trade and other creditors

Trade and other creditors are measured at transaction price, unless payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate. In this case the arrangement constitutes a financing transaction, and the financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

2.10 Operating leases

Leases that do not transfer all the risks and rewards of ownership are classified as operating leases. Payments under operating leases are charged to the Statement of Financial Activities on a straight-line basis over the period of the lease.

2.11 Taxation

The entity is a registered charity (number CHY6100). All of its activities are exempt from direct taxation.

VAT recovered under the VAT Compensation Scheme is recognised as income in the Statement of Financial Activities upon receipt.

NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2020

2. ACCOUNTING POLICIES (continued)

2.12 Employee benefits

Short term benefits

Short term benefits, including holiday pay and other similar non-monetary benefits are recognised as an expense in the period in which the service is received. A liability is recognised to the extent of any unused holiday pay entitlement, which is accrued at the Balance Sheet date and carried forward to future periods. This is measured at the undiscounted salary cost of the future holiday entitlement so accrued at the Balance Sheet date.

Defined contribution pension plans

The company operates two occupational pension schemes, being a defined contribution pension scheme and a personal retirement savings account (PRSA) scheme. Pension benefits are funded over the employees' period of service by way of contributions from the company and from employees. Employer contributions are charged to the Statement of Financial Activities in the year in which they become payable.

Employee benefits are met by payments to a defined contribution pension fund. Contributions are charged to the Statement of Financial Activities in the year in which they fall due. The assets are held separately from those of the Charity in an independently administered fund. Differences between the amounts charged in the Statement of Financial Activities and payments made to pension funds are treated as assets or liabilities.

2.13 Provisions

Provisions are recognised when the Charity has a present legal or constructive obligation as a result of past events; it is probable that an outflow of resources will be required to settle the obligation; and the amount of the obligation can be estimated reliably.

Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole. A provision is recognised even if the likelihood of an outflow with respect to any one item included in the same class of obligations may be small.

NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2020

2. ACCOUNTING POLICIES (continued)

2.14 Contingencies

Contingent liabilities, arising as a result of past events, are not recognised when (i) it is not probable that there will be an outflow of resources or that the amount cannot be reliably measured at the reporting date or (ii) when the existence will be confirmed by the occurrence or non-occurrence of uncertain future events not wholly within the company's control. Contingent liabilities are disclosed in the financial statements unless the probability of an outflow of resources is remote. Contingent assets are not recognised. Contingent assets are disclosed in the financial statements when an inflow of economic benefits is probable.

3. CRITICAL ACCOUNTING JUDGEMENTS AND ESTIMATES

In the application of the Charity's accounting policies, which are described above, the Directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from the other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or the period of the revision and future periods if the revision affects both current and future periods.

a) Critical judgements made in applying the company's accounting policies

Going concern

The Directors have prepared budgets and cash flows for a period of at least twelve months from the date of approval of the financial statements which demonstrate that there is no material uncertainty regarding the company's ability to meet its liabilities as they fall due, and to continue as a going concern.

In making this assessment, the directors have considered the potential impact of COVID-19 and its ongoing impact in 2021 under a number of different scenarios and do not consider the impact will be so significant as to cast doubt on the ability of the organisation to continue in operational existence for the foreseeable future, being 12 months post approval of the financial statements.

The assessment performed is based on a number of key judgements and assumptions including:

- statutory funding will remain stable in early 2022 and will increase later into 2022;
- services will continue to be delivered where possible, given COVID-19 restrictions and funding availability;
- organisational health in terms of staff retention and continuity will improve in late 2021 and into 2022;
- some new services or adaptations to virtual services will be further developed in late 2021 and into 2022, some of which will generate additional income for the Society;
- the plan laid out by the fundraising team to raise the necessary income, focusing on regular giving, unrestricted corporate donations (particularly around a workplace wellness programme and the Society's Clean Air programme of work) and developing growth plans for funding for strategic key programmes from Trusts and Foundations;
- the known cost impacts of COVID-19 have been considered and strictly mitigated against where possible; and
- the Society's ongoing discipline in streamlining costs across all programmes of work.

The Directors acknowledge that 2021 has been a challenging financial year to date, but cost-cutting and a fundraising strategy and accompanying fundraising activities position the Society well to recover in 2022.

On the basis of the assessments and the underlying assumptions the Directors consider it appropriate to prepare the financial statements on a going concern basis.

ASTHMA SOCIETY OF IRELAND

**NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2020**

3. CRITICAL ACCOUNTING JUDGEMENTS AND ESTIMATES (continued)

b) Key sources of estimation uncertainty

There are no estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

4. DONATIONS AND LEGACIES

	Unrestricted funds 2020 €	Restricted funds 2020 €	Total 2020 €	Total 2019* €
Private Members Draw	251,501	-	251,501	359,967
General donations and miscellaneous income	88,885	-	88,885	76,852
Regular givers	23,179	-	23,179	25,984
Community and events	8,805	-	8,805	14,823
Corporate donations	33,550	172,000	205,550	244,506
Legacies and bequests	81,476	-	81,476	5,174
Trust and Foundations	-	59,000	59,000	15,600
GSK Pharmacy Days	-	20,208	20,208	-
TWSS	14,671	-	14,671	-
	502,067	251,208	753,275	742,906

*The comparatives for 2019 were all classified as unrestricted funds with the exception of income from Corporate Donations of €233,362 and Trust and Foundations of €15,600 which were classified as restricted funds. All income derives from activities in the Republic of Ireland.

5. CHARITABLE ACTIVITIES

Unrestricted funds

	2020 €	2019 €
HSE-PC (HCP Programme)	762	-
Sale of asthma devices	3,626	10,017
Consultancy fees	26,316	6,818
	30,704	16,835

ASTHMA SOCIETY OF IRELAND

**NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2020**

5. CHARITABLE ACTIVITIES (continued)

Restricted funds

		2020	2019
Grantor	Grant Name	€	€
POBAL	Slaintecare Project	93,221	13,113
POBAL	SSNO Programme	90,000	79,671
HSE Grant Aid Nat. Lottery	Asthma Friendly Schools	3,000	24,984
HSE DNC	Dublin North Central Services	7,643	7,632
HSE NCPA	HCP e-Learning & NAP	-	7,116
HSE Primary Care	Adviceline	241,700	166,260
HSE Primary Care	HCP Engagement	-	2,249
		435,564	301,025
Other income			
ASI Pharmacy days		490	8,550
		490	8,550
Total restricted funds		436,054	309,575
Total		466,758	326,410

All income from charitable activities derives from activities in the Republic of Ireland.

6. INVESTMENTS

	2020	2019
	€	€
Bank deposit interest	46	47
	46	47

Interest income from cash held on deposit is classified as unrestricted income.

7. COST OF RAISING FUNDS

	2020	2019
	€	€
Asthma devices	7,582	10,972
Private Members Draw	156,358	234,912
Fundraising costs	108,382	100,881
DM Emergency Covid-19 Appeal	14,355	-
	286,677	346,765

All costs incurred in raising funds are spent out of restricted and unrestricted funds.

ASTHMA SOCIETY OF IRELAND

**NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2020**

8. EXPENDITURE ON CHARITABLE ACTIVITIES

Unrestricted funds

	2020	2019
	€	€
Health promotion	4,610	25,618
Support costs (note 9)	279,392	149,340
Communications and campaigns	43,777	34,271
Research and education	-	12,707
Advocacy and policy	15,942	23,292
Health promotion materials	-	1,100
	343,721	246,328

Restricted funds

	2020	2019
	€	€
Health promotion	415,089	258,487
Support costs (note 9)	121,688	77,244
Communications and campaigns	64,937	90,239
Research and education	10,297	71,530
Advocacy and policy	64,017	32,875
Health promotion materials	-	3,266
	676,028	533,641
Total	1,019,749	779,969

ASTHMA SOCIETY OF IRELAND

**NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2020**

9. SUPPORT COSTS

Allocated to unrestricted funds

	2020	2019
	€	€
Finance and administrative costs	22,266	29,923
Premises costs	46,839	37,804
General office and programme management costs	117,546	32,308
HR costs	7,409	22,049
Web support	5,705	5,365
Wages and salaries	20,145	8,358
Governance costs (note 10)	59,482	13,533
	279,392	149,340
	279,392	149,340

Allocated to restricted funds

	2020	2019
	€	€
Finance and administrative costs	72,166	44,361
General office expenses	19,998	2,042
Web support	2,878	7,103
Wages and salaries	26,646	23,738
	121,688	77,244
	121,688	77,244

10. GOVERNANCE COSTS

	2020	2019
	€	€
Auditor's remuneration for statutory audit services (including VAT)	9,888	9,840
Legal fees	49,594	3,693
	59,482	13,533
	59,482	13,533

Legal fees incurred in 2020 mainly relate to the termination of a contract in 2020, and no further legal fees are expected to be incurred in relation to this matter.

11. NET EXPENDITURE

Net expenditure is stated after charging:

	2020	2019
	€	€
Depreciation of tangible fixed assets:		
- owned by the company	2,642	918
Auditor's remuneration	9,888	9,840
Pension costs (note 22)	15,696	12,463
	28,226	23,221
	28,226	23,221

ASTHMA SOCIETY OF IRELAND

**NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2020**

12. STAFF COSTS

The average monthly number of persons employed by the Charity during the year, including full-time and part-time staff, was as follows:

	2020	2019
	No.	No.
Fundraising and communication	2	1
Advocacy	2	2
Health promotion	9	6
Office administration	4	4
	17	13
	17	13

Staff costs were as follows:

	2020	2019
	€	€
Wages and salaries	613,080	418,947
Employer PRSI	65,126	43,849
Pension costs (note 22)	15,696	12,463
	693,901	475,259
	693,901	475,259

2020 was the first year of full funding for the new Beating Breathlessness service, funded by the Sláintecare Integration Fund which involved additional staff being taken on. Two staff members were hired for fixed term contracts to assist the Society in its work to support patients through the COVID-19 pandemic, in part funded by Trusts and Foundations donations.

The Directors do not receive remuneration for their services as members of the Board. Directly incurred expenses are reimbursed, if claimed, and amounted to €Nil (2019: €Nil).

The number of higher paid employees was:

	2020	2019
	No.	No.
In the band €90,000 - €100,000	-	1
In the band €80,000 - €90,000	1	-
In the band €70,000 - €80,000	-	-
In the band €60,000 - €70,000	-	-
	1	1
	1	1

This analysis of salary bands includes basic pay and excludes employer pension and employer PRSI contributions.

The total remuneration of the Chief Executive Officer, which includes employer pension contributions and employer's PRSI, was €100,405.

ASTHMA SOCIETY OF IRELAND

**NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2020**

13. TAXATION

No charge to current or deferred taxation arises as the Charity has been granted charitable status under Sections 207 and 208 of the Taxes Consolidation Act 1997.

14. TANGIBLE FIXED ASSETS

	Fixtures and fittings €	Website development €	Computer equipment €	Total €
Cost				
At 1 January 2020	57,234	29,299	37,609	124,142
Additions	28,375	-	4,173	32,548
Disposals	(57,234)	(29,299)	(37,609)	(124,142)
At 31 December 2020	28,375	-	4,173	32,548
Accumulated depreciation				
At 1 January 2020	57,234	29,299	37,609	124,142
Charge for the year	1,892	-	750	2,642
Disposals	(57,234)	(29,299)	(37,609)	(124,142)
At 31 December 2020	1,892	-	750	2,642
Net book value				
At 31 December 2020	26,483	-	3,423	29,906
At 31 December 2019	-	-	-	-

15. STOCKS

	2020 €	2019 €
Stock of asthma devices	1,212	3,674

16. DEBTORS

	2020 €	2019 €
Trade debtors	30,535	38,901
Accrued revenue	15,950	7,116
Private Members Draw	-	68,019
Prepayments	13,615	8,829
	60,100	122,865

All debtors are due within one year. All trade debtors are due within the Charity's normal terms. There is no allowance for doubtful debts.

ASTHMA SOCIETY OF IRELAND

**NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2020**

17. CREDITORS: Amounts falling due within one year

	2020	2019
	€	€
Trade creditors	49,347	20,274
Taxes and social security costs	19,898	17,897
Deferred income (note 18)	-	24,107
Other creditors	18,077	151,498
Accruals	57,000	26,283
	144,322	240,059
	144,322	240,059

Trade and other creditors

Trade and other creditors are payable at various dates in the next 12 months in accordance with the suppliers' standard terms.

Taxes and social security costs

Taxes and social security costs are subject to the terms of the relevant legislation. Interest accrues on late payment. No interest was due at the financial year end date.

Accruals

The terms of the accruals are based on underlying contracts.

18. DEFERRED INCOME

	2020	2019
	€	€
At beginning of year	24,107	24,533
Received during the year	-	37,216
Credited to the Statement of Financial Activities	(24,107)	(37,642)
At end of year	-	24,107
	-	24,107

Deferred income at 31 December 2019 relates to funding advances of €24,107 received from Pobal for salary costs related to 2020 from the Sláintecare Integration Fund. The Asthma Society of Ireland did not have entitlement to this income at 31 December 2019 and therefore the income was deferred.

19. STATEMENT OF FUNDS

Current year

	Unrestricted funds	Restricted funds	Total funds
	2020	2020	2020
	€	€	€
At 1 January 2020	358,738	79,691	438,429
Income	532,817	687,262	1,220,079
Expenditure	(612,727)	(693,699)	(1,306,426)
Transfer of Funds	4,173	(4,173)	-
At 31 December 2020	283,001	69,081	352,082
	283,001	69,081	352,082

ASTHMA SOCIETY OF IRELAND

**NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2020**

19. STATEMENT OF FUNDS (continued)

Transfer from Restricted Funds to Unrestricted Funds relates to the purchase of fixed assets during 2020.

Prior year

	Unrestricted funds 2019 €	Restricted funds 2019 €	Total funds 2019 €
At 1 January 2019	441,005	54,795	495,800
Income	510,826	558,537	1,069,363
Expenditure	(593,093)	(533,641)	(1,126,734)
At 31 December 2019	358,738	79,691	438,429

20. FUNDS OF THE CHARITY COMPRISE THE FOLLOWING:

Current year

	Unrestricted funds 2020 €	Restricted funds 2020 €	Total funds 2020 €
Tangible fixed assets	29,906	-	29,906
Current assets	397,417	69,081	466,498
Creditors due within one year	(144,322)	-	(144,322)
	283,001	69,081	352,082

Prior year

	Unrestricted funds 2019 €	Restricted funds 2019 €	Total funds 2019 €
Tangible fixed assets	-	-	-
Current assets	598,797	79,691	678,488
Creditors due within one year	(240,059)	-	(240,059)
	358,738	79,691	438,429

ASTHMA SOCIETY OF IRELAND

**NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2020**

21. OPERATING LEASE COMMITMENTS

At 31 December the Charity had commitments under non-cancellable operating leases as follows:

	2020	2019
	€	€
In one year or less	44,280	22,140
In more than one year, but not more than five years	166,050	-
	210,330	22,140
	210,330	22,140

In 2020, the Charity entered a new non-cancellable operating lease for its office space for a lease term of 4 years and 9 months.

22. PENSION COMMITMENTS

The Charity operates a defined contribution scheme for the benefit of its staff. The assets of the scheme are held separately from those of the Charity in independently administered pension funds. Pension costs for the year amounted to €15,696 (2019: €12,463).

23. FINANCIAL INSTRUMENTS

The carrying amount for each category of financial instruments is as follows:

	2020	2019
	€	€
Financial assets that are debt instruments measured at amortised cost:		
Trade debtors	30,535	38,901
Cash at bank and in hand	405,186	551,949
	435,721	590,850
	435,721	590,850
 Financial liabilities measured at amortised cost		
Trade creditors	49,347	20,274
Other creditors	18,077	151,498
Accruals	57,000	26,283
	124,424	198,055
	124,424	198,055

24. CAPITAL COMMITMENTS

There were no capital commitments as at 31 December 2020 (2019: €Nil).

25. COMPANY STATUS

Asthma Society of Ireland is a company limited by guarantee and accordingly does not have a share capital.

Every member of the company undertakes to contribute such amount as may be required not exceeding €5 to the assets of the Charitable Company in the event of its being wound up while he or she is a member.

ASTHMA SOCIETY OF IRELAND

**NOTES TO THE FINANCIAL STATEMENTS (continued)
for the year ended 31 December 2020**

26. RELATED PARTY TRANSACTIONS

Related party transactions

Other than as described below, no related party transactions took place during the year ended 31 December 2020.

Key management personnel compensation

The senior employees who have authority and responsibility for planning, directing and controlling the activities of the company are considered to be key management personnel. Total remuneration in respect of these individuals is €371,515 (2019: €264,383). The uplift in 2020 relates to the addition of key management personnel roles that were unfilled for large parts of 2019 (including Advocacy and Research, Fundraising and Health Promotion positions) together with CEO maternity cover with the appointment of an interim CEO.

27. POST BALANCE SHEET EVENTS

There have been no significant events affecting the Charity since the year-end.

28. APPROVAL OF FINANCIAL STATEMENTS

The financial statements were approved by the Board on 26/10/2021.